Clinical Scorecard: Immune Cell Changes in Cerebrospinal Fluid of Women Experiencing Neuropsychiatric Symptoms Post-COVID-19
At a Glance
Category
Detail
Condition
Neuropsychiatric Long COVID (NP-Long COVID) in women
Key Mechanisms
Compartment-specific immune responses with differential gene expression in CSF and PBMC, including oxidative stress, reactive oxygen species, P53 response, androgen response, MTORC1 signaling, and lipid metabolism pathways
Target Population
Women with documented history of COVID-19 experiencing neuropsychiatric symptoms post-acute infection
Care Setting
Specialized clinical research and neurological evaluation settings involving lumbar puncture and blood sampling
Key Highlights
Women disproportionately affected by neuropsychiatric symptoms following COVID-19 recovery
CSF-specific transcriptional profiles reveal enrichment in cellular stress pathways in NP-Long COVID
Differential gene expression in both CSF and PBMC suggests complex molecular landscape underlying neuropsychiatric symptoms
Guideline-Based Recommendations
Diagnosis
Use WHO definition of Long COVID: symptoms persisting or new after 3 months from SARS-CoV-2 infection onset, lasting at least 2 months, unexplained by alternative diagnosis
Comprehensive medical and psychiatric history taking and standardized surveys to characterize neuropsychiatric symptoms
Consider lumbar puncture for CSF analysis in research or specialized clinical settings
Management
No specific treatments established; management guided by symptomatology and supportive care
Recognition of disproportionate impact on women to tailor monitoring and supportive interventions
Monitoring & Follow-up
Neuropsychological testing battery to assess cognitive and psychiatric symptoms
Longitudinal follow-up to evaluate symptom persistence and progression
Risks
Potential risks associated with lumbar puncture including procedural complications
Exclusion of patients with major pre-existing neurological disorders to avoid confounding
Patient & Prescribing Data
Women with documented SARS-CoV-2 infection and neuropsychiatric Long COVID symptoms
No direct pharmacologic treatment data reported; molecular findings highlight potential pathways for future therapeutic targeting
Clinical Best Practices
Employ standardized definitions and comprehensive phenotyping for Long COVID diagnosis
Incorporate both peripheral blood and CSF analyses to understand compartment-specific immune changes
Use multidisciplinary approaches including neurology, psychiatry, and molecular diagnostics for patient evaluation
by Benjamin Orlinick, Sameet Mehta, Lindsay McAlpine, Saba Khoshbakht, Sofia Fertuzinhos, Allison Nelson, Jennifer Chiarella, Bibhuprasad Das, Vansh Patel, Paraskevas Filippidis, Michael J Corley, Serena S Spudich, Shelli F Farhadian
